ctDNA-MRD Monitoring After Resection in Gastric Cancer

Condition(s) studied

Study summary

Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and early intervention. Our previous retrospective study, using fixed ctDNA-MRD, confirmed that postoperative ctDNA-MRD can predict recurrence risk. Therefore, we plan to conduct a further prospective, multicenter, observational study, utilizing a combination of personalized ctDNA-MRD and fixed MRD panels, to dynamically monitor gastric cancer patients who have received neoadjuvant therapy followed by curative resection. The study will systematically analyze the correlation between ctDNA-MRD status and tumor recurrence and metastasis, assess its sensitivity and specificity in recurrence prediction, and compare its early warning advantage over traditional imaging techniques in predicting recurrence.

Eligibility

Primary outcome measure(s)

• Predictive Accuracy of Personalized ctDNA-MRD for Postoperative Recurrence — From the time of surgical resection to the point of resurrence within 2 years
  Sensitivity, Specificity, and Positive predictive value of ctDNA-MRD in predicting postoperative recurrence

Trial sites (1)

More Peking University trials in China

Other trials for the same condition